PHATHOM PHARMACEUTICALS, INC. (PHAT): Price and Financial Metrics


Today's Latest Price: $29.56 USD

0.13 (0.44%)

Updated Jul 14 11:18am

Add PHAT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

PHAT Daily Price Range
PHAT 52-Week Price Range

PHAT Stock Price Chart Technical Analysis Charts

PHAT Price/Volume Stats

Current price $29.56 52-week high $64.54
Prev. close $29.43 52-week low $18.51
Day low $28.64 Volume 12,379
Day high $30.27 Avg. volume 81,573
50-day MA $39.80 Dividend yield N/A
200-day MA $0.00 Market Cap 856.21M


Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.

PHAT Latest News Stream

Event/TimeNews Detail
Loading, please wait...

PHAT Latest Social Stream

Loading social stream, please wait...

View Full PHAT Social Stream

Latest PHAT News From Around the Web

Below are the latest news stories about Phathom Pharmaceuticals Inc that investors may wish to consider to help them evaluate PHAT as an investment opportunity.

Todd Branning as Phathom Pharma CFO

Phathom Pharmaceuticals ([[PHAT]] +1.3%) appointed 25-year industry veteran Todd Branning as CFO, while interim CFO David Socks, will continue as a strategic advisor and remain on its board.Most recently Mr. Branning served as senior VP and CFO of Amneal Pharmaceuticals ([[AMRX]] +2.6%)....

Seeking Alpha | July 13, 2020

Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer

FLORHAM PARK, N.J., July 13, 2020 -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing.

Yahoo | July 13, 2020

Phathom Pharmaceuticals Provides Clinical Trial Status Update

First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pause Announced in March

GlobeNewswire | June 15, 2020

Hedge Funds Are Selling Phathom Pharmaceuticals, Inc. (PHAT)

In this article we will check out the progression of hedge fund sentiment towards Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

Yahoo | June 13, 2020

The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Fortress Biotech (NASDAQ: FBIO ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Pliant Therapeutics Inc (NASDAQ: PLRX ) (went public Wednesday) Protara Therapeutics Inc (NASDAQ: TARA ) Qiagen NV (NYSE: QGEN ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) United Therapeutics Corporation (NASDAQ:...

Benzinga | June 4, 2020

Read More 'PHAT' Stories Here

PHAT Price Returns

1-mo -40.21%
3-mo 0.48%
6-mo -18.00%
1-year N/A
3-year N/A
5-year N/A
YTD -5.07%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7325 seconds.